Xanthelasma with Normal Lipid Panel: Diagnostic Considerations

Introduction to Diagnostic Challenges

The American College of Cardiology recommends screening for familial hypercholesterolemia (FH) in patients with xanthelasma, even with normal lipid panels, as it is a clinical indicator that should prompt genetic and advanced lipid testing 1, 2
Standard lipid panels can miss FH if the patient is on cholesterol-lowering medications or has recently recovered from acute illness, both of which artificially lower LDL-cholesterol 1, 2

The American Heart Association suggests that LDL-cholesterol concentrations should be adjusted for medication use when phenotypically screening for FH; if diagnosis is uncertain, repeat testing after full recovery from illness 1
Xanthelasma palpebrarum is specifically listed as a clinical sign warranting FH evaluation by ophthalmologists and optometrists, even before lipid abnormalities are confirmed 1, 2
Genetic testing is the gold standard for FH diagnosis and should be pursued when clinical signs like xanthelasma are present, regardless of current lipid values 1, 2

The European Society for Medical Oncology notes that xanthelasma occurs in 25-33% of ECD patients and may be the presenting sign of this potentially fatal histiocytic neoplasm 3, 4
ECD presents with xanthelasma-like yellow eyelid plaques that are clinically indistinguishable from lipid-related xanthelasma 3, 4
Consider ECD when xanthelasma occurs with bone pain, diabetes insipidus, exophthalmos, cardiovascular symptoms, or constitutional symptoms 3, 4

The Endocrine Society states that both inherited and acquired lipodystrophy can cause xanthelasma despite normal or near-normal standard lipid panels 5, 6
Familial partial lipodystrophy (Dunnigan variety) causes severe hypertriglyceridemia and can present with xanthomas 5, 6

The American Diabetes Association recommends screening for diabetes in all xanthelasma patients, as type 2 diabetes causes hypertriglyceridemia with low HDL-cholesterol and small dense LDL particles 5
Poor glycemic control increases hepatic VLDL production and impairs chylomicron clearance 5
Hypothyroidism can cause secondary dyslipidemia and xanthelasma, and thyroid function tests should be obtained in all xanthelasma patients 7

Verify lipid panel accuracy, and consider direct LDL-cholesterol assay if triglycerides are elevated 1, 5
Screen for FH using the Dutch Lipid Clinic Network or Simon Broome criteria, and pursue genetic testing if clinical suspicion exists 1, 2
Evaluate for systemic diseases, including thyroid function tests, diabetes screening, and consideration of histiocytic disorders if systemic symptoms are present 3, 8, 5

Obtain lipid panel and thyroid function tests to identify correctable systemic factors, as recommended by the European Heart Journal, to guide treatment decisions and reduce recurrence risk 9

Shave biopsy of xanthelasma is the least invasive procedure for diagnostic tissue acquisition in patients with suspected Erdheim-Chester Disease, as reported in Blood 10
Xanthelasma represents cutaneous-dominant ECD manifestation occurring in 25-33% of ECD patients, according to Blood 11, 12, 13
Systemic treatment with BRAF inhibitors or MEK inhibitors is indicated for symptomatic multisystem ECD, as recommended in Blood 14, 15
Isolated cutaneous xanthelasma in asymptomatic ECD may be monitored without systemic therapy, as suggested in Blood 15